Cargando…

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database

Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Koki, Mizuno, Tomohiro, Koseki, Takenao, Ito, Yoshimasa, Takahashi, Kazuo, Tsuboi, Naotake, Yamada, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992371/
https://www.ncbi.nlm.nih.gov/pubmed/35401222
http://dx.doi.org/10.3389/fphar.2022.803706
_version_ 1784683716480598016
author Kato, Koki
Mizuno, Tomohiro
Koseki, Takenao
Ito, Yoshimasa
Takahashi, Kazuo
Tsuboi, Naotake
Yamada, Shigeki
author_facet Kato, Koki
Mizuno, Tomohiro
Koseki, Takenao
Ito, Yoshimasa
Takahashi, Kazuo
Tsuboi, Naotake
Yamada, Shigeki
author_sort Kato, Koki
collection PubMed
description Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Adverse event signals were recognized as significant when the reporting odds ratio estimates and lower limits of the corresponding 95% confidence intervals exceeded 1. The use of nivolumab showed a significant signal for vasculitides. Furthermore, significant signals of polymyalgia rheumatica were found when the patients were treated with nivolumab, pembrolizumab, and ipilimumab. In addition, the frequencies of nivolumab- and pembrolizumab-induced polymyalgia rheumatica were higher in patients aged ≥70 years and female patients, respectively. Polymyalgia rheumatica was reported in 38 patients treated with nivolumab; 31 (82%) of these were either in recovery or in remission. Further, polymyalgia rheumatica was reported in 17 patients treated with pembrolizumab; 13 (76%) of these were in recovery or remission, while three (18%) were not. Polymyalgia rheumatica was reported in 12 patients treated with ipilimumab; seven (58%) of these were in recovery or remission. Our study highlights that careful monitoring for the symptom of PMR (e.g., bilateral pain in shoulder and pelvic girdles) is required when the patients are aged >70 years and have been treated with nivolumab and when the patients are women and have been treated with pembrolizumab.
format Online
Article
Text
id pubmed-8992371
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89923712022-04-09 Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database Kato, Koki Mizuno, Tomohiro Koseki, Takenao Ito, Yoshimasa Takahashi, Kazuo Tsuboi, Naotake Yamada, Shigeki Front Pharmacol Pharmacology Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Adverse event signals were recognized as significant when the reporting odds ratio estimates and lower limits of the corresponding 95% confidence intervals exceeded 1. The use of nivolumab showed a significant signal for vasculitides. Furthermore, significant signals of polymyalgia rheumatica were found when the patients were treated with nivolumab, pembrolizumab, and ipilimumab. In addition, the frequencies of nivolumab- and pembrolizumab-induced polymyalgia rheumatica were higher in patients aged ≥70 years and female patients, respectively. Polymyalgia rheumatica was reported in 38 patients treated with nivolumab; 31 (82%) of these were either in recovery or in remission. Further, polymyalgia rheumatica was reported in 17 patients treated with pembrolizumab; 13 (76%) of these were in recovery or remission, while three (18%) were not. Polymyalgia rheumatica was reported in 12 patients treated with ipilimumab; seven (58%) of these were in recovery or remission. Our study highlights that careful monitoring for the symptom of PMR (e.g., bilateral pain in shoulder and pelvic girdles) is required when the patients are aged >70 years and have been treated with nivolumab and when the patients are women and have been treated with pembrolizumab. Frontiers Media S.A. 2022-03-25 /pmc/articles/PMC8992371/ /pubmed/35401222 http://dx.doi.org/10.3389/fphar.2022.803706 Text en Copyright © 2022 Kato, Mizuno, Koseki, Ito, Takahashi, Tsuboi and Yamada. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kato, Koki
Mizuno, Tomohiro
Koseki, Takenao
Ito, Yoshimasa
Takahashi, Kazuo
Tsuboi, Naotake
Yamada, Shigeki
Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
title Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
title_full Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
title_fullStr Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
title_full_unstemmed Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
title_short Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
title_sort frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the japanese adverse drug event report database
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992371/
https://www.ncbi.nlm.nih.gov/pubmed/35401222
http://dx.doi.org/10.3389/fphar.2022.803706
work_keys_str_mv AT katokoki frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase
AT mizunotomohiro frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase
AT kosekitakenao frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase
AT itoyoshimasa frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase
AT takahashikazuo frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase
AT tsuboinaotake frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase
AT yamadashigeki frequencyofimmunecheckpointinhibitorinducedvasculitidesanobservationalstudyusingdatafromthejapaneseadversedrugeventreportdatabase